Label: ME NAPHOS MB HYO 1- urinary antiseptic antispasmodic tablet
- NDC Code(s): 58657-454-01
- Packager: Method Pharmaceuticals
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: unapproved drug other
DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
Updated December 30, 2021
If you are a consumer or patient please visit this version.
Inactive Ingredients include:
Cellulose, Mannitol, Croscarmellose Sodium, Magnesium
Stearate, FD&C Blue #1
HYOSCYAMINE SULFATE is an alkaloid of belladonna.
Exists as a white crystalline powder. Affected by light It
is very soluble in water; freely soluble in alcohol;
practically insoluble in ether.
METHENAMINE exists as colorless, lustrous crystals or
white crystalline powder. Its solutions are alkaline to
litmus. Freely soluble in water; soluble in alcohol and in
METHYLENE BLUE exists as dark green crystals. It is
soluble in water and in chloroform; sparingly soluble in
MONOBASIC SODIUM PHOSPHATE exists as a white
crystalline powder. Its solutions are acidic to litmus. It is
freely soluble in water and practically insoluble in
This product is not an Orange Book (OB) rated
product, therefore all prescriptions using this
product shall be pursuant to state statutes as
applicable. There are no claims of bioequivalence
or therapeutic equivalence.
HYOSCYAMINE is a parasympatholytic which relaxes
smooth muscles and thus produces an antispasmodic
effect. It is well absorbed from the gastrointestinal tract
and is rapidly distributed throughout body tissues. Most
is excreted in the urine within 12 hours, 13% to 50%
Its biotransformation is hepatic. Its protein binding is
METHENAMINE degrades in an acidic urine environment
releasing formaldehyde which provides bactericidal or
bacteriostatic action. It is well absorbed from the
gastrointestinal tract. 70% to 90% reaches the urine
unchanged at which point it is hydrolyzed if the urine is
acidic. Within 24 hours it is almost completely (90%)
excreted; of this amount at pH 5, approximately 20% is
formaldehyde. Protein binding: some formaldehyde is
bound to substances in the urine and surrounding
tissues. Methenamine is freely distributed to body tissue
and fluids but is not clinically significant as it does not
hydrolyze at pH greater than 6.8.
METHYLENE BLUE possesses weak antiseptic properties.
It is well absorbed in the gastrointestinal tract and is
rapidly reduced to leukomethylene blue which is
stabilized in some combination form in the urine. 75%
is excreted unchanged.
MONOBASIC SODIUM PHOSPHATE helps to maintain an
acid pH in the urine necessary for the degradation of
INDICATION AND USAGE
ME/NaPhos/MB/Hyo 1 Tablets is indicated for the
treatment of symptoms of irritative voiding. Indicated
for the relief of local symptoms, such as hypermotility
which accompany lower urinary tract infections and as
antispasmodic. Indicated for the relief of urinary tract
symptoms caused by diagnostic procedures.
(Pregnancy Category C)
hyoscyamine and methenamine cross the placenta.
Studies have not been done in animals or humans. It is
not known whether ME/NaPhos/MB/Hyo 1
Tablets cause fetal harm when administered to a
pregnant woman or can affect reproduction capacity.
ME/NaPhos/MB/Hyo 1 Tablets should be given to
a pregnant woman only if clearly needed.
- Prolonged use
because of this product's effect on gastrointestinal
motility and gastric emptying, it may decrease the
absorption of other oral medications during concurrent
use such as: urinary alkalizers; thiazide diuretics (may
cause the urine to become alkaline reducing the
effectiveness of methenamine by inhibiting its
conversion to formaldehyde); antimuscarinics
(concurrent use may intensify antimuscarinic effects of
hyoscyamine because of secondary antimuscarinic
activities of these medications); antacids/antidiarrheals
(may reduce absorption of hyoscyamine, concurrent use
with antacids may cause urine to become alkaline
reducing effectiveness of methenamine by inhibiting its
conversion to formaldehyde) doses of these medications
should be spaced 1 hour apart from doses of
hyoscyamine; antimyasthenics (concurrent use with
hyoscyamine may further reduce intestinal motility);
ketoconazole (patients should be advised to take this
combination at least 2 hours after ketoconazole);
monoamine oxidase (MAO) Inhibitors (concurrent use
may intensify antimuscarinic side effects, opioid
(narcotic) analgesics may result in increased risk of
severe constipation); sulfonamides (these drugs may
precipitate with formaldehyde in the urine, increasing
the danger of crystalluria).
Patients should be advised that the urine may become
blue to blue green and the feces may be discolored as a
result of the excretion of methylene blue.
- ADVERSE REACTIONS
- DRUG ABUSE AND DEPENDENCE
Emesis or gastric lavage. Slow intravenous
administration of physostigmine in doses of 1 mg to
4 mg (0.5 mg to 1 mg in children), repeated as needed
in one to two hours to reverse severe antimuscarinic
symptoms. Administration of small doses of diazepam to
control excitement and seizures. Artificial respiration
with oxygen if needed for respiratory depression.
Adequate hydration. Symptomatic treatment as
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- OTHER SAFETY INFORMATION
DIRECTIONS: 1 Tablet 4 times daily followed by liberal fluid intake, or
as directed by a physician.
FOR FULL PRODUCT INFORMATION SEE ATTACHED BOOKLET.
Store at 25° C (77° F); excursions permitted to 15° C to 30° C (59° F to
86° F) [See USP Controlled Room Temperature]. Protect from moisture or
NOTE: Patient should be advised that urine will be colored blue while
taking this medication.
PHARMACIST: Preserve and dispense in tight-light resistant container as
defined in the USP.
KEEP THIS AND ALL MEDICINES OUT OF THE REACH OF
Tamper evident by heat seal under cap. Do not use if there is
evidence of tampering.
To report an adverse event, please contact Method
Pharmaceuticals, LLC at (877) 250-3427.
- PRINCIPAL DISPLAY PANEL
INGREDIENTS AND APPEARANCE
ME NAPHOS MB HYO 1
urinary antiseptic antispasmodic tablet
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:58657-454 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength METHENAMINE (UNII: J50OIX95QV) (METHENAMINE - UNII:J50OIX95QV) METHENAMINE 81.6 mg SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN) (PHOSPHATE ION - UNII:NK08V8K8HR) SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 40.8 mg METHYLENE BLUE ANHYDROUS (UNII: 8NAP7826UB) (METHYLENE BLUE CATION - UNII:ZMZ79891ZH) METHYLENE BLUE CATION 10.8 mg HYOSCYAMINE SULFATE ANHYDROUS (UNII: OB570Z127K) (HYOSCYAMINE - UNII:PX44XO846X) HYOSCYAMINE SULFATE ANHYDROUS 0.12 mg Inactive Ingredients Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) CROSCARMELLOSE SODIUM (UNII: M28OL1HH48) MAGNESIUM STEARATE (UNII: 70097M6I30) FD&C BLUE NO. 1 (UNII: H3R47K3TBD) Product Characteristics Color blue (light blue to blue) Score no score Shape OVAL Size 10mm Flavor Imprint Code M455 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:58657-454-01 100 in 1 BOTTLE; Type 0: Not a Combination Product 12/01/2015 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other 12/01/2015 Labeler - Method Pharmaceuticals (060216698)